UNSPSC 51392610: Phenylpropanolamine maleate

This classification denotes an adrenergic agonist with the molecular formula C9H13NO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 86ILV507ZN. Most nations, for tariff and trade purposes, schedule phenylpropanolamine maleate under HS 29394900. As of Q4 2014, PHENYLPROPANOLAMINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]([C@@H](C1CCCCC1)O)N.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51392610 Phenylpropanolamine maleate is a Commodity code that captures pharmaceutical products and related deactivation systems procured by state and local health agencies. Recent solicitations under this code reflect broader procurement activity for naloxone, safe drug deactivation systems, and direct-to-manufacturer prescription fulfillment arrangements rather than the specific active pharmaceutical ingredient named in the code. Issuing bodies include county health departments and state health and human services commissions executing community health initiatives, harm-reduction programs, and pharmacy benefit management reforms. The work spans competitive bidding for packaged pharmaceutical products with quarterly delivery schedules and exploratory market-intelligence gathering to establish direct contracting relationships between state agencies and pharmaceutical manufacturers outside traditional pharmacy benefit manager channels.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring electronic submission through the county's e-Procurement Portal and compliance with drug-free workplace certification and E-Verify requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, reflecting state-level interest in restructuring pharmaceutical procurement outside traditional intermediaries. Activity under the code is concentrated in Florida and Texas, with Florida pursuing direct product procurement and Texas exploring direct manufacturer relationships to support self-insured health plans and government employee pharmacy benefit programs.